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Visceral obesity is coupled to a general low-grade chronic inﬂammatory state characterized by macrophage activation
and inﬂammatory cytokine production, leading to insulin resistance (IR). The balance between proinﬂammatory M1 and
antiinﬂammatory M2 macrophage phenotypes within visceral adipose tissue appears to be crucially involved in the development
of obesity-associated IR and consequent metabolic abnormalities. The ligand-dependent transcription factors peroxisome
proliferator activated receptors (PPARs) have recently been implicated in the determination of the M1/M2 phenotype. Liver
X receptors (LXRs), which form another subgroup of the nuclear receptor superfamily, are also important regulators of
proinﬂammatorycytokineproductioninmacrophages.Disregulationofmacrophage-mediatedinﬂammationbyPPARsandLXRs
therefore underlies the development of IR. This review summarizes the role of PPAR and LXR signaling in macrophages and
current knowledge about the impact of these actions in the manifestation of IR and obesity comorbidities such as liver steatosis
and diabetic osteopenia.
1.Introduction
Progressive development of insulin resistance (IR) is a
prediabetic state which is today a widespread metabolic
abnormality of adults and adolescents in industrialised soci-
eties [1]. Impaired insulin action is considered the ﬁrst stage
of type 2 diabetes mellitus (T2DM). The consequences of IR
manifest at many levels and in many metabolic processes,
producing a cluster of homeostatic abnormalities including
glucose intolerance, overt hyperglycemia, hyperinsulinemia,
and atherogenic dyslipidemia, collectively referred to as
metabolic syndrome (MetS). Liver steatosis, kidney disease,
and osteoporosis are also frequent comorbidities of T2DM
and MetS [2–4].
IR correlates positively with obesity, and the rapidly
growing incidence of T2DM and MetS is therefore often
attributed to lifestyle factors such as excess caloric intake
and insuﬃcient physical exercise in urbanized human pop-
ulations [5]. The main predisposing factor for IR is intra-
abdominal accumulation of adipose tissue (AT), which leads
to central obesity [5, 6]. The total load of visceral adipose
tissue(VAT)andtherateoffreefattyacid(FFA)mobilization
from VAT to the portal venous system are well-established
correlates of IR and high circulating levels of insulin [7–9].
Several mechanisms link visceral adiposity and elevated FFA
levels to IR. The elevated VAT mass liberates excess amount
FFAs to the bloodstream, which contribute to muscle
and liver IR by triggering reduced insulin signaling and
increased hepatic gluconeogenesis. High levels of FFA shift
the substrate preference of mitochondrial oxidation from
glucose to FFA, and this can diminish the insulin secretory
response to glucose of islet β-cells, leading to relative insulin
insuﬃciency [10, 11]. Moreover, FFAs induce an inﬂamma-
tory response in macrophages, adipocytes, and muscle cells
via toll-like receptor (TLR) activated pathways (Figure 1).
Modiﬁed lipoproteins such as oxidized and glycated low-
densitylipoproteinsderivedfromexcessVATcanaccumulate
in certain tissues, including subendothelial spaces, muscle
cells, liver or kidney mesangium and tubular epithelial cells,
where they can give rise to atherogenesis, lipotoxic injury,2 Mediators of Inﬂammation
andinﬂammation[12].VATisalsoanactiveendocrineorgan
able to secrete a wide variety of inﬂammatory cytokines with
key functions in the development of IR [13].
In recent years, macrophages have been recognized as
major sources of proinﬂammatory mediators, which are
largely responsible for the manifestation of IR. Macrophages
are plastic cells and their ability to produce cytokines
is determined by their phenotype. The so-called classical
activated or “M1” macrophages secrete high amounts of
inﬂammatory mediators while the alternatively activated
“M2” macrophages are low cytokine producers. In obesity
the balance between M1 and M2 macrophages is dis-
turbed. Thus, production of inﬂammatory cytokines by
VAT macrophages increases signiﬁcantly [14]. This situa-
tion creates a general subclinical inﬂammatory state [15]
that will ultimately lead to altered insulin responsive-
ness. Recent studies reveal that macrophage activation is
regulated by lipid metabolites through the activation of
nuclear receptor transcription factors, and that imbalances
in macrophage nuclear receptor signaling can lead to IR
[13].
Nuclear receptors (NRs) are a superfamily of ligand-
activated transcription factors that control transcription of
their target genes through direct or indirect mechanisms.
Directly, NRs bind to speciﬁc DNA sequences in cis-
regulatory elements within promoter regions, activating or
repressing target gene expression by recruiting or releasing
coactivators and corepressors [16]. Indirectly, NRs can trans-
repress the transcription of certain genes controlled by
other transcription factors, such as nuclear factor kappa-B
(NF-κB) or activator protein-1 (AP-1) [17, 18]. Prominent
members of the NR superfamily are peroxisome proliferator
activated receptors (PPARs), activated by FFAs, eicosanoids,
and prostaglandins, and liver X receptors (LXRs), activated
by cholesterol metabolites. These “lipid sensors” appear
to play a central role in the control of lipid metabolism.
NRs are moreover the targets of environmental obesogens
such as phtalates, organotins, bisphenol A, and xenobiotics
that interfere with NR signaling and which are thought
to underlie the spread of obesity and its comorbidi-
ties [19]. In addition, evidence acquired over the last
decade demonstrates that PPARs and LXRs have impor-
tant antiinﬂammatory eﬀects and can control macrophage
activation, suggesting potential in the medication of
IR.
The role of NRs in linking metabolism and inﬂamma-
tion is especially relevant to the pathogenesis of obesity-
induced IR. Synthetic pharmacological ligands for PPARγ
(thiazolidinediones; TZDs) and PPARα (ﬁbrates) are used
clinically due to their hypolipidemic and insulin-sensitizing
properties. Additionally, pharmacological activation of LXRs
results in increased HDL levels and net cholesterol loss,
therefore, synthetic LXR ligands have a potential medical
beneﬁttotreatdyslipidaemiasandatherosclerosis.Agrowing
body of literature suggests that these drugs, due to their
antiinﬂammatory eﬀects, can have a broader impact in
metabolic diseases, especially in obesity comorbidities. Here
we summarize the latest ﬁndings linking IR, inﬂammatory
mediators, and macrophages and discuss the regulatory
role of NR signaling in macrophage cytokine production
associated with obesity and obesity comorbidities.
2. Friend or Foe? M1 andM2 Macrophages in
Adipose Tissue
Over the last few years, understanding of macrophages as
an important element of IR development has advanced
considerably with the identiﬁcation of distinct functional
macrophage subsets. Macrophages have a highly plastic
phenotype that allows them to specialize and display
polarized functional properties, such as inﬂammatory or
antiinﬂammatory actions in response to cytokines and
microbial products. Macrophage polarity can be determined
by T-helper cells. Cytokines released by T-helper 1 (Th1)
cells,suchasinterleukin-2(IL-2),gamma-interferon(IFNγ),
and tumor-necrosis factor alpha (TNFα), induce the clas-
sical macrophage phenotype, activating them to stimulate
cellular immunity and inﬂammation. Th1 cells also secrete
granulocyte-macrophage colony stimulating factor (GM-
CSF), which promotes medullar monocyte/macrophage dif-
ferentiation. In contrast, T-helper 2 (Th2) cells secrete
interleukin-4 (IL-4) and interleukin-13 (IL-13), which
induceanalternativephenotypebyattenuatingmacrophage-
mediated secretion of inﬂammatory mediators and instead
inducing macrophage programs for FFA oxidation [20].
Adapting the Th1/Th2 nomenclature, Mantovani and col-
leagues in 2002 started to refer to polarized macrophages as
M1 and M2 cells [21]. M1 macrophages are activated proin-
ﬂammatory cells, while M2 macrophages are characterized
by an antiinﬂammatory phenotype. Although there is a clear
association of obesity and IR with macrophage inﬁltration of
AT and M1 macrophage activation, the dominant phenotype
of adipose tissue macrophages (ATMs) is still an open
debate.
The ﬁrst evidence suggesting diversity of ATM phe-
notype was obtained from chemokine receptor-2 (CCR2)
knockout (KO) mice (CCR2KO) [22]. CCR2 is a cell-
surface receptor for monocyte chemoattractant protein-1
(MCP-1), a chemokine which speciﬁcally mediates mono-
cyte chemotaxis. Under normal physiological conditions,
the ATM content of CCR2KO AT does not diﬀer from
wild-type AT, and CCR2KO mice show no overt metabolic
alteration. However, CCR2KO mice fed a high-fat diet
accumulate fewer ATMs in AT than similarly fed wild-
type mice, and present an attenuated inﬂammatory pro-
ﬁle and greater insulin sensitivity. Thus metabolic chal-
lenge with supernormal fat intake triggers macrophage
recruitment to VAT via a MCP-1/CCR2-dependent pro-
cess, but CCR2 is not required for resident macrophage
recruitment. Brake and co-workers subsequently identiﬁed
CD11c-positive (CD11c+) and CD11c-negative (CD11c−)
macrophage populations in mouse AT [23]. The numbers
of CD11c+ cells increase in response to a high-fat diet,
and this is accompanied by increased AT expression of
transcripts for CCR2, interleukin-6 (IL-6), and intercellu-
lar adhesion molecule I (ICAM-I), a leukocyte adhesion
receptor needed for macrophage tissue inﬁltration. CD11c+
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population in AT. Interestingly, conditional bone marrow
depletion of CD11c+ cells in obese mice results in a rapid
normalization of insulin sensitivity [24]. Moreover, further
studies conﬁrmed that ATMs recruited to AT in diet-induced
obesity express high levels of IL-6, inducible nitric oxide
(NO) synthase (iNOS) and CCR2, all characteristics of
the M1 phenotype [25, 26]. In obese mice chronic iNOS
blockade attenuates high-fat diet induced IR and, similar
to CCR2KO mice, reduces macrophage VAT inﬁltration, as
shown by lowered mRNA expression of MCP-1 and the
macrophage cell surface receptor CD68 [27]. In addition,
resident ATMs show very low (if any) inﬂammatory activity
and express many M2-associated genes such as arginase 1,
interleukin-10 (IL-10) and the secretory chitinase protein
Ym1 [28].
The identiﬁcation of two monocyte populations in
mouse blood [29, 30] supported the hypothesis that M2
macrophages resident in AT are descendents of circulating
nonactivatedmonocytes,whileM1macrophagesderivefrom
a population of circulating inﬂammatory monocytes that are
recruited to AT where they continue their diﬀerentiation and
orchestratetheinﬂammatoryresponse.Thismodelisfurther
supported by the observation that, blood mononuclear
cells from obese patients are in a proinﬂammatory state
[31].
An alternative hypothesis is that M1 macrophage
polarization during obesity progression occurs via in situ
reprogramming of ATMs from an M2 to an M1 pheno-
type. In vitro, it is well established that the pattern of
macrophage function depends on the agonist to which
they are exposed [32]. For instance, in vivo, treatment of
tumor-bearing animals with interleukin-12 (IL-12) shifts
tumor-associated macrophages from a dominant M2 proﬁle
(elevated expression of TGFβ, IL-10, and MCP1) to a proim-
munogenic/inﬂammatory M1 proﬁle (elevated expression of
IL-6andTNFα)[33].However,itremainsuncertainwhether
this “in situ” phenotype switching can also occur in AT
(Figure 1).
Interestingly, PPARγ and PPARδ have been recently
implicated in the transcriptional regulation of monocyte/
macrophage phenotypic shift (Figure 1). Using myeloid-
speciﬁc PPARγ and PPARδ KO mice (Mac-PPARγKO and
Mac-PPARδKO), Odegaard et al. showed that PPARγ and
PPARδ are both necessary for optimal induction of the M2
macrophage phenotype by IL-4 (a classical Th2 cytokine)
[34, 35]. However, these factors make distinct contributions
to this process: PPARγ is speciﬁcally required for IL-4-
dependent activation of fatty acid oxidation, whereas PPARδ
is required for the full expression of the IL-4-dependent
immune phenotype (Figure 1). Furthermore, the AT of fat-
fed Mac-PPARγKO accumulates fewer macrophages and
shows lower M2-related gene expression than the AT of fat-
fed wild-type mice. However, fat-fed Mac-PPARγKO mice
are more obese, indicating that the reduced number of
M2 macrophages leads to major alterations in adipocyte
metabolism [34]. These studies demonstrate that activation
of PPARγ and PPARδ in ATMs ameliorates IR not only
through the regulation of cytokine production but also by
modulating ATM phenotype.
3.NuclearReceptor Signaling
Reduces CytokineProduction by ATMs and
AmelioratesInsulinResistance
The paracrine and endocrine functions of VAT actively
contributetothedevelopmentofIR.VATisamajorsourceof
a wide variety of cytokines produced mainly by macrophages
and of certain hormone-like factors produced by adipocytes.
The best known VAT-produced cytokines include C-reactive
protein (CRP), IL-6, interleukin-1 (IL-1), interleukin-18
(IL-18), and tumor necrosis factor (TNFα)[ 36]. These
inﬂammatory mediators exert their actions not only on AT
cells, but also on other cell types such as hepatocytes, liver
Kuppfer cells, kidney mesangial cells, osteoclasts, and muscle
ﬁbers. Indeed, in T2DM patients, elevated VAT expression of
TNFα is associated with the onset of IR, and high circulating
levelsofinterleukin-1receptorantagonist(IL-1ra)andTNFα
c o r r e l a t es t r o n g l yw i t hM e t Si nh u m a np o p u l a t i o n s[ 37].
The mechanisms by which inﬂammatory cytokines produce
defectsininsulinsignalingarenotfullyunderstood;however,
many studies suggest an origin in insulin postreceptor
signaling. Binding of insulin to its receptor is followed by
phosphorylation of the insulin receptor substrates IRS-1
and IRS-2. Tyrosine phosphorylation of IRS-1 and IRS-2
mediates insulin signaling; however, serine phosphorylation
of IRSs can block downstream signaling. There are thus two
pathways by which cytokines appear to interfere in insulin
signaling: by impairing IRS tyrosine phosphorylation or
by inducing IRS serine phosphorylation [38]. For instance,
TNFα impairs tyrosine phosphorylation mediated by PI3-
kinase, leading to insuﬃcient glucose uptake by muscle
cells [39, 40]. In addition, there is evidence implicating
the serine kinases c-Jun Kinase (JNK) and inhibitor of
NF-κB kinase (IKK) in cytokine-dependent IR: obesity is
associated with increased JNK activity in adipose and liver
tissues [41] and mice lacking IKK-β are resistant to obesity-
induced IR [42]. These kinases also aﬀect AP-1 and NF-
κB transcription factors, promoting further inﬂammatory
gene expression. In addition, SOCS proteins, another class
of inﬂammatory mediators, have been found to be involved
in obesity-induced IR. SOCS proteins block insulin signaling
either by interfering with IRS-1 and IRS-2 phosphorylation
or by targeting IRSs for proteosomal degradation [43, 44].
Studies on PPARs and LXRs indicate that these nuclear
receptors are important regulators of proinﬂammatory
cytokine production by macrophages. In LPS- or IFNγ-
stimulated macrophages, activation of PPARγ represses the
induction of inﬂammatory genes including iNOS, IL-6,
cyclooxygenase-2( COX-2), and matrix metalloproteinase
9 (MMP9) [45, 46]. Activation of LXRs represses almost
the same genes as PPARγ [47, 48], while PPARα shows
a distinct pharmacological proﬁle, inhibiting expression of
tissue factor [49]. Finally, PPARδ deﬁciency in macrophages
is associated with low levels of MMP9 and MCP1 [50].
Recently,increasedcytokineproductionhasbeenreportedin
vivo in the AT, liver, and muscle of myeloid PPARγKO mice,
correlating with the development of IR in these animals [51].
Mostevidenceindicatesthatthebasicmechanismunder-
lying the antiinﬂammatory actions of NRs is interference in4 Mediators of Inﬂammation
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Figure 1: Cytokine release by adipose tissue macrophages contributes to insulin resistance. Free fatty acids (FFAs) released from visceral
adipose tissue (VAT) promote polarization toward the M1 phenotype through activation of Toll-like receptors (TLRs), and also impair
insulin secretion and action. Diﬀerentiation to the M1 phenotype is inhibited by PPARγ signaling, and activation of PPARγ or PPARδ,i n
response to IL-4, promotes polarization toward the M2 phenotype. IL-13 is also suggested to be involved in the M2 phenotype switch.
Inﬂammatory monocytes migrating into VAT can also diﬀerentiate into M1 macrophages. Inﬂammatory mediators produced by M1
ATMs alter insulin responsiveness. CCR2: chemokine receptor-2, TNFα: tumor necrosis factor, iNOS: inducible nitric oxide synthase, IL-
6: interleukin-6, TGF-β: transforming growth factor beta, IL-10: interleukin-10, Ym1: secretory chitinase protein-1, MCP-1: monocyte
chemoattractant protein-1 (MCP-1).
AP-1/NFκB signalling [17, 18]. However, alternative path-
ways are not excluded. For example, mechanisms involving
blockade of the clearance of corepressor complexes from
promoters have recently been proposed. These processes are
thought to involve SUMOylation of PPARγ or LXRs [52].
There thus appears to be no single mechanism of repression,
and pathway selection seems to depend on the signal, the NR
isoform involved, and even the gene promoter.
The ability of PPAR and LXR receptors to control
macrophage-mediated inﬂammation by these mechanisms
appears to have an important impact on the control of IR.
Indeed, the beneﬁcial eﬀect of weight loss on obesity-related
IR might be associated with an improved inﬂammatory
proﬁle in the stromal vascular fraction of AT, which contains
the ATMs [53].
Unlike other AT related proteins, the adipocyte protein,
adiponectin, contributes to the maintenance of insulin
sensitivity and seems to be able to antagonize the proinﬂam-
matory eﬀects of macrophages [54, 55]. Adiponectin is the
most abundant adipocyte-derived factor in the circulation
and low levels of this protein are linked to high body mass
index, IR, dyslipidemia, and increased risk of cardiovascular
disease [56]. Consistently, adiponectin immunostaining is
reduced in the AT of mice fed a fat- and carbohydrate-
rich diet [57]. In humans, a marked gender diﬀerence
in AT distribution evolves during puberty, resulting in
elevated VAT mass and lower adiponectin production in
adult males and an associated higher susceptibility to
insulin signaling defects [58, 59]. Moreover, TNFα reduces
adiponectin production [60]. Importantly, adiponectin also
has a potent antiinﬂammatory action on macrophages,
suppressing lipopolysaccharide (LPS)-stimulated cytokine
production possibly via the antiinﬂammatory IL-10 signal-
ing pathway [61]. Adiponectin promoter is regulated by
PPARγ/RXRαheterodimers,andadministrationofTZDshas
been reported to signiﬁcantly increase plasma adiponectin
concentrations in insulin-resistant humans and rodents
without aﬀecting their body weight [62]. Activation of
PPARγ induces production of adiponectin not only from
adipocytesbutalsofromskeletalmuscle,whichaugmentsthe
antidiabetic actions of PPARγ [63, 64].
4. LiverResident Macrophages Link
ObesitytoSteatosis
The liver is responsible for the coordination of intermediate
metabolism. Hepatocytes are actively involved in glucose
and lipid metabolism (including cholesterol and lipoprotein
synthesis), plasma protein synthesis, and the production
of inﬂammatory proteins such as CRP [65]. Obesity is
associated with a high incidence of steatosis, a pathological
accumulation of lipids within hepatocytes. Nonalcoholic
fatty liver disease (NAFLD) is the most common form of
chronic liver disease and is characterized by excess liver lipidMediators of Inﬂammation 5
accumulation and hepatic IR. At a later stage of disease
progression, NAFLD can occur with hepatic inﬂammation,
leading to nonalcoholic steatohepatitis (NASH) and culmi-
nating in hepatic ﬁbrosis or cirrhosis [3].
In obesity, inﬂammatory cytokines (IL-1β,T N F α,a n d
IL-6) and adiponectin released from AT reach the liver
through the portal vein and can directly interfere with
liver functions. In an inﬂammatory state, TNFα can trigger
hepatocyte apoptosis and the activation of the ﬁbrogenic
response in stellate cells [66], while IL-6 is implicated
in the induction of the acute phase response by eliciting
transcriptional activation of CRP [67]. Adiponectin, unlike
cytokines, appears to have a protective eﬀect in the liver.
Adiponectin administration ameliorates steatosis, probably
via inhibition of TNFα signaling. In addition, adiponectin
exerts antiﬁbrogenic eﬀects: adiponectin KO mice exposed
to CCL4 develop more severe ﬁbrosis than wild-type animals
[68].
However, the most important sources of inﬂammatory
cytokines within the liver are Kupﬀer cells, the resident
macrophages in the liver. Kupﬀer cells mostly localize in
the liver sinusoids but can also migrate into the space of
Disse. Like all macrophages, they show phenotypic plasticity,
presenting diﬀerent morphology and functions depending
on their intralobular position. Kupﬀer cells located in the
periportal zone are large cells with high phagocytosis capac-
ityandhighlysosomalproteaseactivity,whereasKupﬀercells
inmid-zonalandperivenousareasaresmallerandhavelower
protease activity [69, 70]. During steatosis, the recruitment
of new macrophages into the liver can alter cell distribution,
therebyalsochangingKupﬀercellmorphologyandfunction.
Indeed, in the livers of NASH patients, enlarged Kupﬀer cells
occur in aggregates around the perivenous regions, while in
simple steatosis their distribution is more diﬀuse [71]. There
is also evidence that Th1 immune response dominates in
NAFLD, promoting the classical M1 activation of Kupﬀer
cells [72, 73]. In addition, recent studies in rodents suggest a
direct role for Kupﬀer cell M1 activation in hepatic fatty acid
metabolism and steatosis [74, 75]. Interestingly, Kupﬀer cells
from rats, fed a high-fat diet or challenged with endotoxin,
produce high levels of NO and the TNFα M1 cytokine
[76, 77]. Moreover, the depletion of Kupﬀer cells prevents
steatosis and the development of insulin resistance [78]. In
mice, Kupﬀer cell depletion is also associated with a decrease
in hepatic triglyceride levels and increased expression of key
genes involved in fatty acid oxidation, such as PPARα [79].
The ability of PPARs and LXRs to reduce cytokine produc-
tion in activated inﬂammatory monocyte-macrophage cells
is well documented [45–47]. However, the eﬀects of nuclear
receptor agonists on activated Kupﬀer cells remain unclear.
Some studies show that pioglitazone, a clinically available
ligand of PPARγ, prevents endotoxin-induced liver injury
via a mechanism dependent on suppression of TNFα and
NO production by Kupﬀer cells [76, 77]. In mouse liver,
PPARα activation is associated with Kupﬀer-cell mediated
reactive oxygen species production and carcinogenesis [80].
Moreover, case reports indicate that therapeutic use of
PPARα ligands can lead to hepatic ﬁbrosis [81]. Contrary
to these observations, PPARα upregulation has been shown
to ameliorate experimentally-induced liver steatosis in rats
[82]. Thus the common thread linking PPARα activation,
Kupﬀer cells, and hepatic pathologies remains undeﬁned
[83].
Kupﬀer cells can also be alternatively activated, and
PPARδ has recently been shown to be required for this
M2 activation of Kupﬀer cells (Figure 2(a)). Expression of
M2 related genes in Kupﬀer cells is reduced in PPARδ-
deﬁcient lean mice, and transplantation of PPARδ-null bone
marrow into wild-type mice is enough to trigger hepatic
dysfunction and systemic IR [35], probably due to reduced
M2 activation of resident hepatic macrophages. In a similar
way, myeloid-speciﬁc PPARδ−/− mice fed a high-fat diet
gain more weight, acquire a higher body weight/liver weight
ratio, and have a more profound steatosis than control
animals [84]. Moreover, M2 markers are downregulated
in these animals. PPARδ is thus an interesting potential
pharmacological target for the induction of M2 activation to
control inﬂammation and improve steatosis in NAFLD.
5. Osteoclastogenesis inObesityLeadsto
Bone Mass Reduction
Clinical studies indicate that IR conditions such T2DM
and severe obesity are associated with increased fracture
risk although not always with low bone mass [2, 85–87].
Despite this association, T2DM has been classically coupled
tohigherbonemineraldensity(BMD)[88].Itislikelythatin
humans diabetic bone is more fragile due to changes in bone
architecture rather than as a consequence of the reduced
BMD. Furthermore, leptin-deﬁcient obese (ob/ob) mice, a
m o d e lo fo b e s i t ya n dI R ,h a v eac o m p l e xb o n ep h e n o t y p e ,
displaying increased trabecular bone volume in the spine but
short femora with reduced cortical thickness and reduced
trabecular volume [89]. Therefore, although IR is clearly
associated with bone fragility, a direct eﬀect of IR on BMD
is highly controversial. There is also a disputed association
of obesity-associated bone fragility with several IR-derived
defects, such as high insulin levels, low insulin-like growth
factor-1synthesis,lowserumadiponectin,andelevatedlevels
of inﬂammatory cytokines.
Under IR conditions, a compensatory hyperinsulinemia
develops. Insulin appears to be anabolic for bone, and recent
clinical studies demonstrate that elevated insulin levels can
increase BMD [90]. Adiponectin serum levels decrease with
obesity, but osteoblasts and osteoclasts express receptors
for adiponectin [91, 92], indicating a direct role of this
factor in the regulation of bone homeostasis. Some reports
linking obesity with increased BMD have demonstrated that
adiponectin can promote bone resorption [93, 94]. In con-
trast, a recent study reports that adiponectin inhibits osteo-
clastogenesis in primary human cells in vitro and stimulates
osteoblast growth [95]. These contradictory results suggest
that the direct action of adiponectin on bone increases BMD,
but that the ﬁnal sum of its direct and indirect actions leads
to bone mass reduction. Moreover, bone architecture and
mechanical properties unrelated to BMD can be impaired
in patients with T2DM, possibly due to the lowered levels
of insulin-like growth factor-1, a characteristic alteration6 Mediators of Inﬂammation
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Figure 2: Tissue-resident macrophages are sources and targets of
inﬂammatory mediators in obesity. (a) Liver-resident macrophages
(Kupﬀer cells) are major sources of inﬂammatory cytokines in
obesity and IR. Free fatty acids (FFAs) and oxidized low density
lipoproteins (oxLDL) released from VAT promote M1 phenotype
polarization through activation of TLRs. The switch to the M2
phenotype is promoted by PPARδ signaling. Inﬂammatory medi-
ators (IL-6, TNFα,a n dI L - 1 β) originating from M1 Kupﬀer cells or
adipose tissue macrophages (ATMs) induce hepatocyte apoptosis,
IR, and lipid accumulation. (b) Osteoclastogenesis is induced by
ATM-derived inﬂammatory cytokines in obesity and IR. Activation
of PPARs blocks osteoclastogenesis and impedes bone loss, while
LXR promotes osteoclast resorptive activity.
in systemic IR. Finally, inﬂammatory cytokines, including
CRP, IL-1, IL-6, and TNFα, accelerate bone turnover and
osteoclastogenesis,andmayleadtoreducedBMDinhumans
[96–99]. Indeed, cytokine plasma levels can predict bone
resorption in aged adults [100]. These studies illustrate the
complexity of bone physiology and its paracrine/endocrine
metabolic control, which makes it diﬃcult to clarify the
relationship between low bone mass, obesity, and IR.
Nevertheless, increased osteoclast activity and decreased
osteoblast diﬀerentiation are the basis of BMD loss. Bone
homeostasis is maintained by the equilibrium between the
activities of bone-forming osteoblasts and bone-resorbing
osteoclasts. Osteoclasts are derived from haematopoietic
myeloid bone marrow progenitors whereas osteoblasts and
adipocytes originate from bone marrow mesenchymal stem
cells [101, 102]. Given the importance of crosstalk between
macrophages and adipocytes in obesity progression, the fact
that macrophages and osteoclasts, and likewise adipocytes
and osteoblasts, share common precursors suggests the
existence of important interactions between bone and fat.
Osteoclasts and osteoblasts also produce factors capable of
inﬂuencing AT biology, such as osteocalcin or osteopontin.
Osteocalcin is secreted by osteoblasts and modulates the
expression of various genes in adipocytes and insulin secret-
ing β-cells in pancreatic islets [103]. Osteopontin, which
is produced by various cell types such as macrophages,
hepatocytes and osteoclasts, promotes inﬂammation and
macrophage accumulation in AT [104]. These ﬁndings
suggest that bone has endocrine functions through which
it might be involved in obesity progression [105]. However,
there is little published research into the possible contribu-
tion of crosstalk between fat and bone to the regulation of
energy balance.
Paradoxically, administration of the insulin sensitizing
synthetic ligands of PPARγ can induce bone loss and
increase the risk of bone fractures [106, 107]. In mice,
activationofPPARγ withTZDspromotesosteoclastdiﬀeren-
tiation and consequent bone resorption [107]. Consistently,
macrophage-speciﬁc deletion of PPARγ leads to elevated
BMD due to altered osteoclast activity [108]. It is also doc-
umented that PPARγ can control osteoblast diﬀerentiation
from common bone marrow mesenchymal precursors of
the osteoblast/adipocyte lineages [109]. Mice with PPARγ
haploinsuﬃciency therefore also have high BMD, coupled
with reduced bone marrow adiposity [110]. LXRs are also
required for a correct osteoclast function (Figure 2(b)). LXR
KO mice show a signiﬁcantly increased BMD coupled to
paradoxicallyelevatednumberofosteoclastsincorticalbone,
suggesting that LXRs promote osteoclast resorption activity
but is not necessary for osteoclast diﬀerentiation [111].
Conversely, ligands of PPARγ,P P A R α,a n dP P A R δ were
recently shown to inhibit the formation of multinucleated
osteoclasts from human blood monocytes in vitro [112]
(Figure 2(b)).
The use of insulin sensitizing and hypolipidemic drugs,
such as PPAR and LXR ligands, might, by decreasing BMD,
be related to the increased fracture risk observed in T2DM
patients. However, it is still unknown to what extent BMD
contributes to increased fracture risk and whether IR has a
direct eﬀect on BMD.
6. Concluding Remarks
Insulin resistance is the fundamental cause of a broad range
of metabolic abnormalities including glucose intolerance,
overt hyperglycemia, hyperinsulinemia, atherogenic dyslipi-
demia, cardiovascular diseases, kidney disease, liver steatosis,Mediators of Inﬂammation 7
and osteoporosis. Obesity-associated chronic inﬂamma-
tion is a key contributor to decreased insulin signaling
throughout the disease progression, although the speciﬁc
mechanisms that link inﬂammation to IR remain not fully
understood.
The latest advances in the understanding of macrophage
biology place macrophages as the drivers of this
inﬂammatory response. Recruitment of M1 inﬂammatory
macrophages and increased cytokine production in AT and
liver not only perpetuate inﬂammation in these organs
but also inﬂuence other tissue functions. For instance,
obesity-associated inﬂammatory eﬀects on bone physiology
are well documented in many clinical studies. However,
the results are controversial and diﬃcult to interpret, and
there is therefore a need for further studies to address this
question and clarify whether IR has direct eﬀects on bone
homeostasis.
The functions of PPAR and LXR nuclear receptors in
macrophages include the control of both metabolic and
inﬂammatory pathways. Activation of these receptors thus
acts as a link between these two processes closely related to
thedevelopmentofIR.Alargebodyofevidenceclearlyshows
that the insulin-sensitizing properties of NRs are, at least
in part, a result of inﬂammatory control in macrophages.
A better understanding of the molecular mechanisms by
which NRs control macrophage activation would therefore
facilitate the development of pharmacological strategies to
speciﬁcally target pathways regulating obesity before the
onset of obesity-associated complications.
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